Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer

M. Patricia Rivera, Frank C. Detterbeck, Mark A. Socinski, Dominic T. Moore, Martin J. Edelman, Thierry M. Jahan, Rafat H. Ansari, James D. Luketich, Guangbin Peng, Matthew Monberg, Coleman K. Obasaju, Richard J. Gralla

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Several chemotherapy agents, including gemcitabine and paclitaxel, have been reported to cause interstitial pneumonitis. The incidence of pulmonary toxicity from the combination of gemcitabine and paclitaxel is reported to be approximately 5%. In this report, pulmonary function test (PFT) results were analyzed from two similar randomized phase 2 trials that tested platinum and nonplatinum regimens preoperatively in patients with stage I or II non-small cell lung cancer (NSCLC). Methods: The regimens included gemcitabine plus carboplatin, paclitaxel, or cisplatin. PFT and dyspnea scores were obtained at baseline and postchemotherapy, and were compared to one of several secondary end points, including ability to undergo surgical resection. Results: Baseline PFT scores varied with smoking status. Mean levels of diffusing capacity of the lung for carbon monoxide (DLCO) adjusted for hemoglobin declined 8% from pre- to postinduction (Wilcoxon signed rank test, p < 0.0001). Changes in FVC, FEV1, and total lung capacity were not statistically significant after chemotherapy. Although 27% of patients in the study had some reduction in PFT results, only 2 of the 85 eligible patients did not undergo surgery due to PFT reduction following chemotherapy. One patient in the study experienced a clinically significant respiratory toxicity (grade 3 dyspnea). Pulmonary toxicity was only statistically associated with male gender. Conclusion: In the preoperative setting, gemcitabine-based chemotherapy was well tolerated. The most commonly affected PFT parameter postchemotherapy was the DLCO. Although 15% of patients had a significant reduction in the DLCO postchemotherapy, it did not correlate with clinical symptoms or affect the ability to undergo surgical resection.

Original languageEnglish (US)
Pages (from-to)1588-1595
Number of pages8
JournalChest
Volume135
Issue number6
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

gemcitabine
Respiratory Function Tests
Non-Small Cell Lung Carcinoma
Drug Therapy
Aptitude
Paclitaxel
Dyspnea
Lung Volume Measurements
Total Lung Capacity
Lung
Carboplatin
Interstitial Lung Diseases
Carbon Monoxide
Nonparametric Statistics
Platinum
Hemoglobins
Smoking
Incidence

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Rivera, M. P., Detterbeck, F. C., Socinski, M. A., Moore, D. T., Edelman, M. J., Jahan, T. M., ... Gralla, R. J. (2009). Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. Chest, 135(6), 1588-1595. https://doi.org/10.1378/chest.08-1430

Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. / Rivera, M. Patricia; Detterbeck, Frank C.; Socinski, Mark A.; Moore, Dominic T.; Edelman, Martin J.; Jahan, Thierry M.; Ansari, Rafat H.; Luketich, James D.; Peng, Guangbin; Monberg, Matthew; Obasaju, Coleman K.; Gralla, Richard J.

In: Chest, Vol. 135, No. 6, 01.06.2009, p. 1588-1595.

Research output: Contribution to journalArticle

Rivera, MP, Detterbeck, FC, Socinski, MA, Moore, DT, Edelman, MJ, Jahan, TM, Ansari, RH, Luketich, JD, Peng, G, Monberg, M, Obasaju, CK & Gralla, RJ 2009, 'Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer', Chest, vol. 135, no. 6, pp. 1588-1595. https://doi.org/10.1378/chest.08-1430
Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM et al. Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. Chest. 2009 Jun 1;135(6):1588-1595. https://doi.org/10.1378/chest.08-1430
Rivera, M. Patricia ; Detterbeck, Frank C. ; Socinski, Mark A. ; Moore, Dominic T. ; Edelman, Martin J. ; Jahan, Thierry M. ; Ansari, Rafat H. ; Luketich, James D. ; Peng, Guangbin ; Monberg, Matthew ; Obasaju, Coleman K. ; Gralla, Richard J. / Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. In: Chest. 2009 ; Vol. 135, No. 6. pp. 1588-1595.
@article{076613a312ae401996cab2fc23576015,
title = "Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer",
abstract = "Background: Several chemotherapy agents, including gemcitabine and paclitaxel, have been reported to cause interstitial pneumonitis. The incidence of pulmonary toxicity from the combination of gemcitabine and paclitaxel is reported to be approximately 5{\%}. In this report, pulmonary function test (PFT) results were analyzed from two similar randomized phase 2 trials that tested platinum and nonplatinum regimens preoperatively in patients with stage I or II non-small cell lung cancer (NSCLC). Methods: The regimens included gemcitabine plus carboplatin, paclitaxel, or cisplatin. PFT and dyspnea scores were obtained at baseline and postchemotherapy, and were compared to one of several secondary end points, including ability to undergo surgical resection. Results: Baseline PFT scores varied with smoking status. Mean levels of diffusing capacity of the lung for carbon monoxide (DLCO) adjusted for hemoglobin declined 8{\%} from pre- to postinduction (Wilcoxon signed rank test, p < 0.0001). Changes in FVC, FEV1, and total lung capacity were not statistically significant after chemotherapy. Although 27{\%} of patients in the study had some reduction in PFT results, only 2 of the 85 eligible patients did not undergo surgery due to PFT reduction following chemotherapy. One patient in the study experienced a clinically significant respiratory toxicity (grade 3 dyspnea). Pulmonary toxicity was only statistically associated with male gender. Conclusion: In the preoperative setting, gemcitabine-based chemotherapy was well tolerated. The most commonly affected PFT parameter postchemotherapy was the DLCO. Although 15{\%} of patients had a significant reduction in the DLCO postchemotherapy, it did not correlate with clinical symptoms or affect the ability to undergo surgical resection.",
author = "Rivera, {M. Patricia} and Detterbeck, {Frank C.} and Socinski, {Mark A.} and Moore, {Dominic T.} and Edelman, {Martin J.} and Jahan, {Thierry M.} and Ansari, {Rafat H.} and Luketich, {James D.} and Guangbin Peng and Matthew Monberg and Obasaju, {Coleman K.} and Gralla, {Richard J.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1378/chest.08-1430",
language = "English (US)",
volume = "135",
pages = "1588--1595",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer

AU - Rivera, M. Patricia

AU - Detterbeck, Frank C.

AU - Socinski, Mark A.

AU - Moore, Dominic T.

AU - Edelman, Martin J.

AU - Jahan, Thierry M.

AU - Ansari, Rafat H.

AU - Luketich, James D.

AU - Peng, Guangbin

AU - Monberg, Matthew

AU - Obasaju, Coleman K.

AU - Gralla, Richard J.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Background: Several chemotherapy agents, including gemcitabine and paclitaxel, have been reported to cause interstitial pneumonitis. The incidence of pulmonary toxicity from the combination of gemcitabine and paclitaxel is reported to be approximately 5%. In this report, pulmonary function test (PFT) results were analyzed from two similar randomized phase 2 trials that tested platinum and nonplatinum regimens preoperatively in patients with stage I or II non-small cell lung cancer (NSCLC). Methods: The regimens included gemcitabine plus carboplatin, paclitaxel, or cisplatin. PFT and dyspnea scores were obtained at baseline and postchemotherapy, and were compared to one of several secondary end points, including ability to undergo surgical resection. Results: Baseline PFT scores varied with smoking status. Mean levels of diffusing capacity of the lung for carbon monoxide (DLCO) adjusted for hemoglobin declined 8% from pre- to postinduction (Wilcoxon signed rank test, p < 0.0001). Changes in FVC, FEV1, and total lung capacity were not statistically significant after chemotherapy. Although 27% of patients in the study had some reduction in PFT results, only 2 of the 85 eligible patients did not undergo surgery due to PFT reduction following chemotherapy. One patient in the study experienced a clinically significant respiratory toxicity (grade 3 dyspnea). Pulmonary toxicity was only statistically associated with male gender. Conclusion: In the preoperative setting, gemcitabine-based chemotherapy was well tolerated. The most commonly affected PFT parameter postchemotherapy was the DLCO. Although 15% of patients had a significant reduction in the DLCO postchemotherapy, it did not correlate with clinical symptoms or affect the ability to undergo surgical resection.

AB - Background: Several chemotherapy agents, including gemcitabine and paclitaxel, have been reported to cause interstitial pneumonitis. The incidence of pulmonary toxicity from the combination of gemcitabine and paclitaxel is reported to be approximately 5%. In this report, pulmonary function test (PFT) results were analyzed from two similar randomized phase 2 trials that tested platinum and nonplatinum regimens preoperatively in patients with stage I or II non-small cell lung cancer (NSCLC). Methods: The regimens included gemcitabine plus carboplatin, paclitaxel, or cisplatin. PFT and dyspnea scores were obtained at baseline and postchemotherapy, and were compared to one of several secondary end points, including ability to undergo surgical resection. Results: Baseline PFT scores varied with smoking status. Mean levels of diffusing capacity of the lung for carbon monoxide (DLCO) adjusted for hemoglobin declined 8% from pre- to postinduction (Wilcoxon signed rank test, p < 0.0001). Changes in FVC, FEV1, and total lung capacity were not statistically significant after chemotherapy. Although 27% of patients in the study had some reduction in PFT results, only 2 of the 85 eligible patients did not undergo surgery due to PFT reduction following chemotherapy. One patient in the study experienced a clinically significant respiratory toxicity (grade 3 dyspnea). Pulmonary toxicity was only statistically associated with male gender. Conclusion: In the preoperative setting, gemcitabine-based chemotherapy was well tolerated. The most commonly affected PFT parameter postchemotherapy was the DLCO. Although 15% of patients had a significant reduction in the DLCO postchemotherapy, it did not correlate with clinical symptoms or affect the ability to undergo surgical resection.

UR - http://www.scopus.com/inward/record.url?scp=66649094446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66649094446&partnerID=8YFLogxK

U2 - 10.1378/chest.08-1430

DO - 10.1378/chest.08-1430

M3 - Article

VL - 135

SP - 1588

EP - 1595

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -